Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations

Alemtuzumab is a humanized anti-CD52 monoclonal antibody approved in more than 65 countries for the treatment of relapsing–remitting multiple sclerosis (RRMS). Compared with subcutaneous interferon-beta-1a, alemtuzumab significantly reduced clinical disease activity and the rate of brain volume loss...

Descripción completa

Detalles Bibliográficos
Autores principales: Devonshire, Virginia, Phillips, Richard, Wass, Hilary, Da Roza, Gerald, Senior, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182701/
https://www.ncbi.nlm.nih.gov/pubmed/29525836
http://dx.doi.org/10.1007/s00415-018-8822-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182701/
https://www.ncbi.nlm.nih.gov/pubmed/29525836
http://dx.doi.org/10.1007/s00415-018-8822-y

Ejemplares similares